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Abstract 
 
The recent flood tide of recalls of sartan generics due to 
carcinogenic impurities has brought to the forefront the issue of 
the safety and efficacy of generic drugs. Several of these issues 
are discussed in this editorial. Rhythmos 2019;14(2):23-26.   
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Angiotensin-receptor blockers (ARBs) or sartans are 
among the most widely used medicines for hypertension 
and heart failure. A lot of commotion has been raised 
recently over the problem of successive global recalls of 
several generic preparations of ARBs (“sartans”) because 
of carcinogenic impurities (three substances discovered to 
date: NDMA, NDEA and NMBA; see discussion below) 
detected initially in valsartan products by the European 
Medicines Agency (EMA) and the US Food and Drug 
Administration (FDA) which issued recall orders, while 
other authorities followed closely with similar recalls. 1, 2 
If one resorts to Wikipedia (https://en.wikipedia.org/wiki/ 
Valsartan), one will find the following excerpt about this 
serious health problem:  
 
“On July 6, 2018, the EMA recalled certain batches of 
valsartan and valsartan/HCT film-coated tablets 
distributed in 22 countries in Europe, plus Canada.[26] 
Zhejiang Huahai Pharmaceutical Co. (ZHP) in Linhai, 
China manufactured the bulk ingredient contaminated by 
N-nitrosodimethylamine (NDMA), a carcinogen. The 
active pharmaceutical ingredient was subsequently 
imported by a number of generic drug-makers, including 
Novartis, and marketed in Europe and Asia under their 
subsidiary Sandoz labeling, and in the UK by Dexcel 
Pharma Ltd and Accord Healthcare.[26] In Canada, the 
recall involves 5 companies and a class action suit has been 
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initiated by a private law firm.[27][28] Authorities believe the 
degree of contamination is negligible, and advise those 
taking the drug to consult a doctor and not to cease taking 
the medication abruptly. On July 12, 2018, The National 
Agency of Drug and Food Control (NA-DFC or Badan 
POM Indonesia) announced voluntary recalls for two 
products containing valsartan produced by Actavis 
Indonesia and Dipa Pharmalab Intersains.[29] On July 13, 
2018, the FDA announced voluntary recalls of certain 
supplies of valsartan and valsartan/hydrochlorothiazide in 
the U.S. distributed by Solco Healthcare LLC, Major 
Pharmaceuticals, and Teva Pharmaceutical Industries.[30] 
Hong Kong's Department of Health initiated a similar 
recall.[31] On August 2, 2018, the FDA published two 
lengthy, updated lists, classifying hundreds of specific 
U.S. products containing valsartan into those included 
versus excluded from the recall.[32] A week later, the FDA 
cited 2 more drugmakers, Zhejiang Tianyu Pharmaceuticals 
of China and Hetero Labs Limited of India, as additional 
sources of the contaminated valsartan ingredient.[33] In 
September the FDA announced that retesting of all 
valsartan supplies had found a second carcinogenic 
impurity, N-nitrosodiethylamine (NDEA), in the recalled 
products made by ZHP in China and marketed in the U.S. 
under the Torrent Pharmaceuticals (India) brand.[34] 
According to a 2018 Reuters analysis of national 
medicines agencies’ records, more than 50 companies 
around the world have recalled valsartan mono-
preparations or combination products manufactured from 
the tainted valsartan ingredient. The contamination has 
likely been present since 2012 when the manufacturing 
process was changed and approved by EDQM and FDA 
authorities. Based on inspections in late 2018, both 
agencies have suspended the Chinese and Indian 
manufacturers' certificates of suitability for the supply of 
valsartan in the EU and the US.[35] Although the brand 
name Diovan was recalled due to the presence of the 
contaminant NDMA, not all forms of valsartan are recalled 
or contaminated.[36]” 
 
N-nitroso-dimethyl-amine (NDMA) is an organic 
chemical that forms in both industrial and natural 
processes, and has been used to make liquid rocket fuel, 
softeners, and lubricants.2 NDMA is a known animal 
carcinogen. The US Environmental Protection Agency 
found a link between NDMA and liver cancer, but NDMA 
exposure may also be associated with bladder, renal, 
pancreatic, intestinal, colon, and stomach cancers. The 
presence of this impurity in generic sartan preparations 
was attributed to changes in the manufacturing process of 
the active substance effected since 2012.3 The impurity 
was found incidentally while performing tests other than 
routine batch-release specification assessments.  
 
Unfortunately, this calamity was not limited to generic 
valsartan preparations and two more sartans, irbesartan and 
losartan, were found to be plagued by the same impurities. 
Thus, the recall was subsequently expanded to these other 
sartan products as impurities were detected in the 
irbesartan API (active pharmaceutical ingredient) 
produced by India’s Aurobindo and in losartan products 
made using an API from China’s ZHP. Thus, the presence 
of carcinogenic and mutagenic impurities in the ARB 
drugs containing tetrazole ring has led to worldwide 
product recalls.1  This huge health problems points to a gap 
in current pharmaceutical industry practice that escaped 
Drug controlling authorities’ attention.  
 
Recently, to appease the public’s concern over this 
widespread problem, the FDA published a list of 40 “safe” 
sartan generics free of carcinogen impurities 
(www.fda.gov/Drugs/DrugSafety/ucm634620.htm). 
Furthermore, the FDA has added a site with Qs&As on this 
story, i.e. about impurities found in certain generic ARB 
products (https://www.fda.gov/Drugs/DrugSafety/ 
ucm626122.htm). On 1/2/2019, the EMA issued a 
directive for manufacturers regarding the allowed NDEA 
or NDMA impurities in their products (< 0.03 parts per 
million) and called them to review their manufacturing 
processes to avoid presence of nitrosamine impurities, 
allowing them a 2-year transition period to comply 
(https://www.ema.europa.eu/en/news/sartan-medicines-
companies-review-manufacturing-processes-avoid-
presence-nitrosamine-impurities).  
 
Columnists writing about this sartan contamination 
story indicate “So we’re going to have to think about the 
way that synthetic routes in the generic API business are 
monitored” (https://blogs.sciencemag.org/pipeline/ 
archives/2019/01/04/the-sartan-contamination-story). 
Unfortunately, the story does not seem to come to a close 
soon, as more recalls continue to be issued, either 
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voluntarily by manufacturers or when detected by 
Authorities, reflected in the title “Another Day, Another 
ARB, Another Contaminant” recently posted when a third 
carcinogenic nitrosamine impurity, N-Nitroso-N-methyl-
4-aminobutyric acid (NMBA), was discovered in sartan 
generics (losartan lots) (https://www.medpagetoday.com/ 
cardiology/hypertension/78320).  As per the information 
about this impurity that one can find in PubChem 
(https://pubchem.ncbi.nlm.nih.gov/compound/61445-55-
4#section=Biological-Test-Results), studies have shown 
that NMBA is a known animal carcinogen as it can cause 
cancer in rats such as bladder cancers, which renders it a 
potential human carcinogen. What will happen next in this 
saga of sartan recalls remains to be seen. For sure, this has 
been an overly costly oversight on part of regulatory 
Authorities with an ongoing impact 
(https://pharma.nridigital.com/ pharma_feb19/a_costly_ 
oversight_the_ongoing_impact_of_the_valsartan_recall).   
 
In the end, the question arises whether the problem is 
with the Authorities’ control over the manufacturers or it 
is a problem inherent to the manufacturing process of the 
generic drugs. In the case of sartans, carcinogenic 
impurities came from multiple API manufacturers (Table 
1) that synthesize related sartan molecules and then sell 
them to companies that make the final tablets that reach 
consumers (https://pubs.acs.org/doi/10.1021/cen-09708-
scicon1). The four API manufacturers that produced the 
impure sartans are Zhejiang Huahai Pharmaceutical (ZHP) 
based in China and Hetero Labs, Mylan Laboratories, and 
Aurobindo Pharma, all based in India. First, ZHP was 
forced to disclose the presence of the NDMA impurity 
after receiving a complaint from a drug company customer 
in June 2018 about an unidentified impurity in valsartan 
API that the customer received from ZHP. Meanwhile, the 
FDA’s scientists estimate that patients had been taking the 
generic drugs from the recalled batches for 4 years before 
they were actually recalled; and by ingesting the 
carcinogenic impurity continuously for 4 years, a new 
cancer case may arise among 8000 recipients.  
Generic drugs are widely used worldwide to decrease 
pharmaceutical expenditures for patients and payers. 3 All 
relevant properties of the active ingredient in a given 
generic should be identical with those of the original 
brand-name drug. However, drug excipients may differ 
greatly. To ensure pharmacokinetic similarity between the 
generic and the branded medicine, generics should 
undergo comparative bioavailability and bioequivalence 
studies in humans before being licensed. Several issues 
and concerns regarding the reliability of this process have 
been voiced, 4 while the FDA has recognized the problems 
related to the initial regulations about this process and 
changed them in 2004. 5 Some of us remember the major 
problem that emerged with the initial introduction of a 
generic formulation of the classical quinidine gluconate 
drug available as “Quinaglute” in the US, when our 
patients who were previously controlled on the branded 
drug were returning with arrhythmia recurrences to find 
out that the only reason for this was a recent switch to the 
generic formulation.  
 
Table 1. Recallled Sartan Generics, Detected 
Carcinogenic Impurities and Companies Involved 
 
Sartans Valsartan, Irbesartan, Losartan 
Carcinogenic 
Impurities 
NDMA, NDEA, NMBA 
Companies Zhejiang Huahai Pharmaceutical Co. 
(ZHP), Linhai, China 
Novartis, Switzerland  
Sandoz, Germany  
Mylan Laboratories, US 
Dexcel Pharma Ltd, UK  
Accord Healthcare, UK 
Actavis, UK & Indonesia  
Dipa Pharmalab Intersains, Indonesia 
Zhejiang Tianyu Pharmaceuticals, China  
Hetero Labs Limited /Camber, India 
Torrent (AvKare, Legacy) Pharmaceuti-
cals, India 
Aurobindo Pharma, India & US 
Solco Healthcare LLC / Prinston 
Pharmaceutical Inc, US  
Major Pharmaceuticals, US  
Teva Pharmaceutical Industries, Israel & 
US 
Pro Doc, Laval, QC, Canada 
Pfizer, US & Japan 
Camber Pharmaceuticals, US 
ScieGen Pharmaceuticals (GSMS), 
Singapore 
 
NDEA = N-nitrosodiethylamine; NDMA = N-nitrosodimethyl 
amine; NMBA = N-Nitroso-N-methyl-4-aminobutyric acid  
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Further to the problems related to generics, there is the 
issue of pseudogenerics or authorized generics, 
considered to be “exact copies” of the brand-name drug, 
for which, health authorities do not require in vivo 
comparative bioavailability tests to license them. 
Pseudogenerics or authorized generics are commonly 
marketed by brand‐name manufacturers to maintain 
market share after loss of market exclusivity. 6 Some have 
even proposed comparisons to be conducted of authorized 
generic products to other generic drug products to serve as 
useful routine assessments of the performance of the 
generics relative to brand‐name products in real‐world 
settings. 6 However, there are still problems even with this 
type of generics; in two of these pseudogenerics, 
carcinogenic impurities (NDMA) were detected and led to 
their recall; these were NDMA-contaminated generic 
valsartan formulations manufactured in Canada by Sandoz 
Valsartan and Pro Doc. 3  
 
In conclusion, the saga of sartan recalls due to 
carcinogenic impurities detected in a large number of 
tainted sartan products continues and brings about the issue 
of reliability of the industry of generics with problems 
identified in the manufacturing process and the steps and 
measures taken, or their lack thereof, by the Regulatory 
Authorities in controlling this process and ensuring the 
safety and efficacy of the generic medicines.  
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